Clinical Trial

A Phase Ⅱa Clinical Study of CL-197 Capsules

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study will evaluate the antiretroviral activity, safety and pharmacokinetics of single dose of CL-197 capsule in three dose groups administered to antiretroviral treatment-naïve adult participants with human immunodeficiency virus type 1 (HIV-1) infection.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-22.
Trial Details
NCT Number NCT07308782
Lead Sponsor Henan Genuine Biotech Co., Ltd.
Conditions HIV-1 Infection
Enrollment 24 participants
Start Date 2025-11-29
Primary Completion 2026-12 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2026-01-06